{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:56:46Z","timestamp":1786982206116,"version":"build-2736575974"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T00:00:00Z","timestamp":1711324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T00:00:00Z","timestamp":1711324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Natural Science Basic Research Program of Shaanxi","award":["No. 2021JZ-35"],"award-info":[{"award-number":["No. 2021JZ-35"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-024-02309-5","type":"journal-article","created":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T03:02:50Z","timestamp":1711335770000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The efficacy and safety of PD-1 inhibitor combined with TACE in the first-line treatment of unresectable hepatocellular carcinoma"],"prefix":"10.1007","volume":"41","author":[{"given":"Qing-Qing","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-Xu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongchen","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong-Yi","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Mei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,25]]},"reference":[{"issue":"2","key":"2309_CR1","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/ijc.32723","volume":"147","author":"JL Petrick","year":"2020","unstructured":"Petrick JL, Florio AA, Znaor A, et al. International trends in hepatocellular carcinoma incidence, 1978\u20132012. Int J Cancer. 2020;147(2):317\u201330.","journal-title":"Int J Cancer"},{"issue":"1","key":"2309_CR2","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/hep.29086","volume":"67","author":"JK Heimbach","year":"2018","unstructured":"Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358\u201380.","journal-title":"Hepatology"},{"issue":"4","key":"2309_CR3","doi-asserted-by":"publisher","first-page":"297","DOI":"10.14740\/jocmr2496w","volume":"8","author":"K Liu","year":"2016","unstructured":"Liu K, Min XL, Peng J, et al. The changes of HIF-1\u03b1 and VEGF expression after TACE in patients with hepatocellular carcinoma. J Clin Med Res. 2016;8(4):297.","journal-title":"J Clin Med Res"},{"issue":"4","key":"2309_CR4","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1111\/j.1572-0241.2007.01712.x","volume":"103","author":"A Sergio","year":"2008","unstructured":"Sergio A, Cristofori C, Cardin R, et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Off J Am Coll Gastroenterol. 2008;103(4):914\u201321.","journal-title":"Off J Am Coll Gastroenterol"},{"issue":"12","key":"2309_CR5","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/nrgastro.2015.173","volume":"12","author":"J Prieto","year":"2015","unstructured":"Prieto J, Melero I, Sangro B. Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2015;12(12):681\u2013700.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2309_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.764923","volume":"12","author":"Y Wu","year":"2022","unstructured":"Wu Y, Lin H, You X, et al. Immune checkpoint blockade in Chinese patients with hepatocellular carcinoma: characteristics and particularity. Front Oncol. 2022;12: 764923.","journal-title":"Front Oncol"},{"issue":"6","key":"2309_CR7","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.jhep.2012.01.008","volume":"56","author":"M Burrel","year":"2012","unstructured":"Burrel M, Reig Mar\u00eda, Forner A, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. Implications for clinical practice and trial design. J Hepatol. 2012;56(6):1330\u20135.","journal-title":"J Hepatol"},{"issue":"3","key":"2309_CR8","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1159\/000492535","volume":"7","author":"M Kudo","year":"2018","unstructured":"Kudo M. Proposal of primary endpoints for TACE combination trials with systemic therapy: lessons learned from 5 negative trials and the positive TACTICS trial. Liver cancer. 2018;7(3):225\u201334.","journal-title":"Liver cancer"},{"issue":"1","key":"2309_CR9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.drudis.2019.11.003","volume":"25","author":"S Singh","year":"2020","unstructured":"Singh S, Hassan D, Aldawsari HM, et al. Immune checkpoint inhibitors: a promising anticancer therapy. Drug Discov Today. 2020;25(1):223\u20139.","journal-title":"Drug Discov Today"},{"issue":"2","key":"2309_CR10","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jceh.2019.01.004","volume":"9","author":"A Jindal","year":"2019","unstructured":"Jindal A, Thadi A, Shailubhai K. Hepatocellular carcinoma: etiology and current and future drugs. J Clin Exp Hepatol. 2019;9(2):221\u201332.","journal-title":"J Clin Exp Hepatol"},{"issue":"3","key":"2309_CR11","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1200\/JCO.19.01307","volume":"38","author":"RS Finn","year":"2020","unstructured":"Finn RS, Ryoo BY, Merle P, et al. KEYNOTE-240 investigators. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol. 2020;38(3):193\u2013202.","journal-title":"J Clin Oncol"},{"issue":"10088","key":"2309_CR12","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate-040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492\u2013502.","journal-title":"Lancet"},{"key":"2309_CR13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ctrv.2018.08.006","volume":"74","author":"X Chang","year":"2019","unstructured":"Chang X, Lu X, Guo J, et al. Interventional therapy combined with immune checkpoint inhibitors: emerging opportunities for cancer treatment in the era of immunotherapy. Cancer Treat Rev. 2019;74:49\u201360.","journal-title":"Cancer Treat Rev"},{"key":"2309_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/JHC.S187121","volume":"7","author":"P Singh","year":"2020","unstructured":"Singh P, Toom S, Avula A, et al. The immune modulation effect of locoregional therapies and its potential synergy with immunotherapy in hepatocellular carcinoma. J Hepatocell Carcinoma. 2020;7:11\u20137.","journal-title":"J Hepatocell Carcinoma"},{"issue":"11 Supplement 6","key":"2309_CR15","first-page":"16","volume":"17","author":"P Number","year":"2021","unstructured":"Number P. IMMUTACE: a phase 2 single-arm, open-label study of transarterial chemoembolization in combination with nivolumab performed for intermediate-stage hepatocellular carcinoma. Gastroenterol Hepatol. 2021;17(11 Supplement 6):16\u20137.","journal-title":"Gastroenterol Hepatol"},{"issue":"5","key":"2309_CR16","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.jhep.2019.01.027","volume":"70","author":"TF Greten","year":"2019","unstructured":"Greten TF, Mauda-Havakuk M, Heinrich B, et al. Combined locoregional-immunotherapy for liver cancer. J Hepatol. 2019;70(5):999\u20131007.","journal-title":"J Hepatol"},{"key":"2309_CR17","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/hep.31424","volume":"73","author":"R Kloeckner","year":"2021","unstructured":"Kloeckner R, Galle PR, Bruix J. Local and regional therapies for hepatocellular carcinoma. Hepatology. 2021;73:137\u201349.","journal-title":"Hepatology"},{"issue":"7","key":"2309_CR18","doi-asserted-by":"publisher","first-page":"499","DOI":"10.2217\/fon-2022-0916","volume":"19","author":"P Fessas","year":"2023","unstructured":"Fessas P, Scheiner B, D\u2019Alessio A, et al. PETAL protocol: a phase Ib study of pembrolizumab after transarterial chemoembolization in hepatocellular carcinoma. Future Oncol. 2023;19(7):499\u2013507.","journal-title":"Future Oncol"},{"issue":"6","key":"2309_CR19","doi-asserted-by":"publisher","first-page":"e004205","DOI":"10.1136\/jitc-2021-004205","volume":"10","author":"B Marinelli","year":"2022","unstructured":"Marinelli B, Kim E, D\u2019Alessio A, et al. Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective propensity score-matched study. J Immunother Cancer. 2022;10(6):e004205.","journal-title":"J Immunother Cancer"},{"key":"2309_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.816198","volume":"12","author":"R You","year":"2022","unstructured":"You R, Xu Q, Wang Q, et al. Efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: a prospective, multi-center, real-world study. Front Oncol. 2022;12: 816198.","journal-title":"Front Oncol"},{"key":"2309_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.667555","volume":"11","author":"J Chao","year":"2021","unstructured":"Chao J, Zhu Q, Chen D, et al. Case report: transarterial chemoembolization in combination with tislelizumab downstages unresectable hepatocellular carcinoma followed by radical salvage resection. Front Oncol. 2021;11: 667555.","journal-title":"Front Oncol"},{"issue":"1","key":"2309_CR22","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s12885-022-09325-6","volume":"22","author":"Y Guo","year":"2022","unstructured":"Guo Y, Ren Y, Chen L, et al. Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma. BMC Cancer. 2022;22(1):270.","journal-title":"BMC Cancer"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-024-02309-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-024-02309-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-024-02309-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T01:07:54Z","timestamp":1717031274000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-024-02309-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,25]]},"references-count":22,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["2309"],"URL":"https:\/\/doi.org\/10.1007\/s12032-024-02309-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3369412\/v1","asserted-by":"object"}]},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,25]]},"assertion":[{"value":"14 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors who participate in this study have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"This study was approved by the Ethics Committee of Xijing Hospital of the Air Force Military Medical University (Ethical code: KY20232147-C-1).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"91"}}